- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Curtis Triplitt, PharmD, on Patient-Centered Diabetes Care
In this interview, Curtis Triplitt, PharmD, associate professor and assistant dean of research, Texas Tech University Health Sciences Center, Permian Basin, explains why diabetes should be treated with a patient-centered approach.
In this interview, Curtis Triplitt, PharmD, associate professor and assistant dean of research, Texas Tech University Health Sciences Center, Permian Basin, explains why diabetes should be treated with a patient-centered approach. This means that therapies should be based on an individual, not a population. Patient-centered approaches require payer and provider to examine a patient’s specific characteristics and needs such as race, gender, comorbidities, and motivation. “You take those different characteristics of a patient, apply them to a particular drug, and see if they fit,” said Dr Triplitt. He compared prescribing a DPP-4 inhibitor, a well- tolerated once-a day-oral medication that fits well in a large population, with pramlintide, used in combination with insulin and in a smaller population.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Trump Administration Walks Back Mental Health Parity in Insurance Coverage
May 13th 2025The Trump administration has decided to further debate the federal rule passed during the Biden administration that guaranteed insurance coverage for treatment of mental illness and substance abuse.
Read More
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
